RLAY NASDAQ
Relay Therapeutics, Inc.
1W: +2.1%
1M: +6.5%
3M: +2.6%
YTD: +130.3%
1Y: +174.6%
3Y: +178.3%
5Y: -42.2%
$18.84
+0.72 (+3.97%)
Weekly Expected Move ±7.6%
$15
$17
$18
$20
$21
Credit Risk of going bust: lower than 76% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Relay Therapeutics, Inc. would be worth roughly what it owes.
Total debt $30.7M against a stock market value of $4.13B.
Distance to default 8.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.3M (short-term plus half of long-term), stock volatility 63.1%; Altman Z'' 8.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Relay Therapeutics, Inc. would be worth roughly what it owes.
Total debt $30.7M against a stock market value of $4.13B.
Distance to default 8.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.3M (short-term plus half of long-term), stock volatility 63.1%; Altman Z'' 8.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-04-16
Earliest Filing
2024-01-08
Latest Filing
partner: 4
investor: 1
target: 1
Counterparties (Filed by RLAY)
6 relationshipsCompanies named in RLAY's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Nextech Crossover I SCP | — | investor | Purchaser of 2,500,000 shares of common stock in a private placement for approximately $30 million. | 2024-01-08 | View |
| Goldman Sachs & Co. LLC | GSCE | partner | Lead underwriter for the public offering of common stock. | 2022-09-15 | View |
| Cowen and Company, LLC | — | partner | Lead underwriter for the public offering of common stock. | 2022-09-15 | View |
| Goldman Sachs & Co. LLC | GSCE | partner | Lead underwriter for the public offering of common stock. | 2021-10-14 | View |
| Cowen and Company, LLC | — | partner | Underwriter for the public offering of common stock. | 2021-10-14 | View |
| ZebiAI Therapeutics, Inc. | — | target | Target company in a merger agreement to be acquired by Relay Therapeutics, Inc. | 2021-04-16 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Material Agreement; Earnings Release; Exhibits | Agreement | View |
| 2026-06-09 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-21 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-19 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-27 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-16 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-03-11 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-03 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-11 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-06 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-04 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement | Agreement | View |
| 2025-05-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-12-11 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR